Lagevrio should be administered as soon as possible after a diagnosis of COVID-19 has been made and within 5 days of symptom onset (see section 5.1). The safety and efficacy of molnupiravir when administered for periods longer than 5 days have not The recommended dose of Lagevrio is 800 mg (four 200 mg capsules) taken orally every 12 hours for 5 days. 4.2 Posology and method of administration Posology Adults Lagevrio is indicated for treatment of mild to moderate coronavirus disease 2019 (COVID-19) in adults with a positive SARS-COV-2 diagnostic test and who have at least one risk factor for developing severe illness (see sections 4.2 and 5.1 for information on posology and limits of clinical trial population). Clinical particulars 4.1 Therapeutic indications Swedish Orange, opaque, size 0 (approximately 21.7 mm x 7.6 mm) hard capsule, printed with MSD corporate logo on the cap and “82” on the body in white ink. Qualitative and quantitative compositionĮach hard capsule contains 200 mg of molnupiravir.įor the full list of excipients, see section 6.1. See section 4.8 for how to report adverse reactions. Healthcare professionals are asked to report any suspected adverse reactions. This will allow quick identification of new safety information. This medicinal product is subject to additional monitoring.

Half life 3 pre alpha